Accordingly, by increasing the expression NKG2D ligands on tumor cells [158], PARPi can potentially contribute to foster the function of NK cells and activated CD8+ T cells, further highlighting the feasibility of combining PARPi and immunostimulatory therapies for the treatment of AML. The gene discussed is KLRK1; the disease is acute myeloid leukemia.